Across >$9 billion invested in dermatology companies from 2002-2021, annual deal counts, total investment value, and the range of deal sizes have increased, while average investment size and post-investment company valuations decreased; funding was largely directed to pharmaceuticals/biotechnology, though historical maximum funding amounts for clinics/outpatient services, health information technology, and medical devices were achieved in 2021.